Treatment tailored therapy of diffuse large B-cell non hodgkin's lymphoma /
تحديد طريقة علاج حالات أورام الغدد الليمفاوية غير الهودجكن ذات الخلايا الكبيرة حسب كل حالة مرضية
Ahmed Mohammad Mohi Eldin Ali ; Supervised Hussain Mostafa Khaled , Nadia Mahmoud Mokhtar , Foaad Mohammad AbuTaleb
- Cairo : Ahmed Mohammad Mohi Eldin Ali , 2012
- 175 P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical
CD20-positive diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of new cases of lymphoma. DLBCL is a heterogeneous disease that includes at least two prognostically important subtypes (i.e. germinal center B-cell like [GCB] and non-germinal center B-cell like [non-GCB]). These subtypes initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining
CD20-positive diffuse large B-cell lymphoma R-CHOP Rituximab